Ex vivo expansion of tumor-reactive T Cells by means of bryostatin 1/Ionomycin and the common gamma chain cytokines formulation

Journal of Visualized Experiments

Volumn , Issue 47, 2011, Pages

  Kmieciak, Maciej ^a   Toor, Amir ^a   Graham, Laura ^a   Bear, Harry D ^a   Manjili, Masoud H ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Adoptive T cell therapy; Breast Cancer; Bryostatin 1; Common gamma chain cytokines; HER 2 neu; Immunology; Ionomycin; Issue 47

Indexed keywords

BRYOSTATIN; BRYOSTATIN 1; IONOMYCIN;

ADOPTIVE IMMUNOTHERAPY; ANIMAL; ARTICLE; DRUG EFFECT; EXPERIMENTAL NEOPLASM; FEMALE; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METHODOLOGY; MOUSE; T LYMPHOCYTE; TRANSGENIC MOUSE;

ANIMALS; BRYOSTATINS; FEMALE; IMMUNOTHERAPY, ADOPTIVE; IONOMYCIN; LYMPHOCYTE ACTIVATION; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, TRANSGENIC; T-LYMPHOCYTES;

EID: 84873035870     PISSN: 1940087X     EISSN: None     Source Type: Journal    
DOI: 10.3791/2381     Document Type: Article

References (12)

1. Goodell, V., Waisman, J., Salazar, L.G., de la Rosa, C., Link, J., Coveler, A.L., Childs, J.S., Fintak, P.A., Higgins, D.M. & Disis, M.L. Level of HER-2/neu protein expression in breast cancer may affect the development of endogenous HER-2/neu-specific immunity. Mol Cancer Ther. 7, 449-454 (2008).
2. Disis, M.L., Knutson, K.L., Schiffman, K., Rinn, K. & McNeel, D.G. Pre-existent immunity to the HER-2/neu oncogenic protein in patients with HER-2/neu overexpressing breast and ovarian cancer. Breast Cancer Res Treat. 62, 245-252 (2000).
3. Liu, S., Riley, J., Rosenberg, S. & Parkhurst, M. Comparison of common gamma-chain cytokines, interleukin-2, interleukin-7, and interleukin-15 for the in vitro generation of human tumor-reactive T lymphocytes for adoptive cell transfer therapy. J. Immunother. 29, 284-293 (2006).
4. Bear, H.D., Roberts, J., Cornell, D., Tombes, M.B., Kyle, B. Adoptive immunotherapy of cancer with pharmacologically activated lymph node lymphocytes: a pilot clinical trial. Cancer Immunol Immunother. 5, 269-274 (2001).
5. Morales, J.K., Kmieciak, M., Graham, L., Feldmesser, M., Bear, H.D. & Manjili, M.H. Adoptive transfer of HER2/neu-specific T cells expanded with alternating gamma chain cytokines mediate tumor regression when combined with the depletion of myeloid-derived suppressor cells. Cancer Immunol Immunother. 58, 941-953 (2009).
6. Cha, E., Graham, L., Manjili, M.H. & Bear H.D. IL-7 + IL-15 are superior to IL-2 for the ex vivo expansion of 4T1 mammary carcinoma-specific T cells with greater efficacy against tumors in vivo. Breast Cancer Res Treat. 2009 Oct 14. [Epub ahead of print]
7. Guy, C.T., Webster, M.A., Schaller, M., Parsons, T.J., Cardiff, R.D. & Muller W.J. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc. Natl. Acad. Sci. U. S. A. 89, 10578-10582 (1992).
8. Kmieciak, M., Morales, J.K., Morales, J., Bolesta, E., Grimes, M. & Manjili M.H. Danger signals and nonself entity of tumor antigen are both required for eliciting effective immune responses against HER-2/neu positive mammary carcinoma: implications for vaccine design. Cancer Immunol Immunother. 57, 1391-1398 (2008).
9. Stern, J.B. & Smith, K.A. Interleukin-2 induction of T-cell G1 progression and c-myb expression. Science. 233, 203-206 (1986).
10. Kittipatarin, C. & Khaled, A.R. ex vivo expansion of memory CD8 T cells from lymph nodes or spleen through in vitro culture with interleukin-7. J Immunol Methods. 344, 45-57 (2009).
11. Kokaji, A.I., Hockley, D.L. & Kane, K.P. IL-15 transpresentation augments CD8+ T cell activation and is required for optimal recall responses by central memory CD8+ T cells. J Immunol. 180, 4391-401 (2008).
12. Le, H.K., Graham, L., Miller, C.H., Kmieciak, M., Manjili M.H. & Bear, H.D. Incubation of antigen-sensitized T lymphocytes activated with bryostatin 1 + ionomycin in IL-7 + IL-15 increases yield of cells capable of inducing regression of melanoma metastases compared to culture in IL-2. Cancer Immunol Immunother. 58, 1565-1576 (2009).